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Prostate cancer (PCa) is dependent on androgen receptor signaling and aberrations of the PI3K-Akt-mTORC1
pathway mediating excessive and sustained growth signaling. The nutrient-sensitive kinase mTORC1 is upregulated
in nearly 100% of advanced human PCas. Oncogenic mTORC1 signaling activates key subsets of mRNAs that
cooperate in distinct steps of PCa initiation and progression. Epidemiological evidence points to increased dairy
protein consumption as a major dietary risk factor for the development of PCa. mTORC1 is a master regulator of
protein synthesis, lipid synthesis and autophagy pathways that couple nutrient sensing to cell growth and cancer.
This review provides evidence that PCa initiation and progression are promoted by cow´s milk, but not human milk,
stimulation of mTORC1 signaling. Mammalian milk is presented as an endocrine signaling system, which activates
mTORC1, promotes cell growth and proliferation and suppresses autophagy. Naturally, milk-mediated mTORC1
signaling is restricted only to the postnatal growth phase of mammals. However, persistent consumption of cow´s
milk proteins in humans provide highly insulinotropic branched-chain amino acids (BCAAs) provided by milk´s fast
hydrolysable whey proteins, which elevate postprandial plasma insulin levels, and increase hepatic IGF-1 plasma
concentrations by casein-derived amino acids. BCAAs, insulin and IGF-1 are pivotal activating signals of mTORC1.
Increased cow´s milk protein-mediated mTORC1 signaling along with constant exposure to commercial cow´s milk
estrogens derived from pregnant cows may explain the observed association between high dairy consumption and
increased risk of PCa in Westernized societies. As well-balanced mTORC1-signaling plays an important role in
appropriate prostate morphogenesis and differentiation, exaggerated mTORC1-signaling by high cow´s milk
consumption predominantly during critical growth phases of prostate development and differentiation may exert
long-term adverse effects on prostate health. Attenuation of mTORC1 signaling by contemporary Paleolithic diets
and restriction of dairy protein intake, especially during mTORC1-dependent phases of prostate development and
differentiation, may offer protection from the most common dairy-promoted cancer in men of Western societies.
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Prostate cancer (PCa) is the most commonly diagnosed
malignancy in males living in highly developed and
industrialized countries of Europe and North America.
In these Western countries high PCa incidence rates be-
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reproduction in any medium, provided the orwhile incidence rates of PCa in western, southeastern
and eastern Asia and eastern and northern Africa range
between 10 and 20 per 100,000 per year [1]. There were
an estimated 217,730 new PCa diagnoses and 32,050
deaths in the United States during 2010, which makes
PCa the second leading cause of cancer death in men.
Several lines of evidence confirmed that Western diet is
related to PCa risk and outcome [2-5]. In addition, per
capita consumption of milk and dairy products corre-
lates positively with both PCa incidence and mortality
[6,7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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consumption and prostate cancer
Diets of wealthy well-developed countries are character-
ized by high dairy protein and meat consumption. In
Japan the mortality of PCa increased 25-fold linearly
after World War 2 associated with an increase in the in-
take of milk (20-fold), meat (9-fold) and eggs (7-fold),
respectively [8]. The Health Professionals Study demon-
strated a strong association between calcium intake and
prostate cancer risk [9]. Dairy proteins are a significant
dietary source of calcium. In Western diets, dairy pro-
tein-associated calcium is predominantly provided by
high and increasing consumption of cheese exemplified
by the per capita cheese consumption in Germany from
1935 to 2011 (Figure 1). Whereas, Giovannucci et al. [9]
suggested that high calcium intake might increase pros-
tate carcinogenesis by lowering serum concentrations of
1,25-dihydroxyvitamin D [1,25(OH)2D], they could not
exclude a role of “additional cancer-promoting factors in
the nonfat component” of dairy products. The European
Prospective Investigation into Cancer and Nutrition
examined animal food, protein and calcium consump-
tion and the risk of PCa in 142,251 men during an 8.7-
year prospective study period and confirmed a strong as-
sociation between high intake of dairy protein and
increased risk of PCa [10]. An increase of 35 g/day in
consumption of dairy protein was associated with an in-
crease in the risk of PCa of 32% [10].
Remarkably, calcium from dairy products was posi-
tively associated with PCa risk, but not calcium from
other foods [10]. This observation questions the role of
dairy-derived calcium and points to a more critical role
of the milk protein fraction itself. In fact, Ahn et al. [11]
found no association between calcium intake and serum
concentrations of 25-hydroxy-vitamin D [25(OH)D] andFigure 1 Annual increase of per capita cheese consumption in Germa
leucine. Cheese consumption steadily increased in industrialized countries1,25(OH)2D. Moreover, the calcium-vitamin-D hypoth-
esis has been challenged at the level of cell biology by
Heaney [12]. Thus, recent lines of evidence do not sup-
port the formerly suggested “high calcium intake/low
vitamin D hypothesis” of dairy-mediated prostate
tumorigenesis [9]. In this paper, evidence will be pro-
vided that the intrinsic signaling capability of the dairy
protein itself is the most critical nutritional factor linking
milk and dairy products to the pathogenesis of PCa.
Several ecological, cohort and case control studies
conducted in various countries [6,8-11,13-21] have pro-
vided evidence for the association between increased
milk and dairy intake and increased risk of PCa, which
has been confirmed by meta-analyses and systematic
reviews [22-25]. However, two studies, the prospective
cohort study of Rodriguez et al. [26] and the meta-ana-
lysis of Huncharek et al. [27], did not find an association
between dairy product intake and increased risk of PCa.
In contrast, Raimondi et al. [21] recently reported a
two-fold increased risk of PCa associated with high
intakes of dairy products. Ganmaa et al. [6] have ana-
lyzed the incidence and mortality rates of PCa in 42
countries and identified “milk + cheese” as a major risk
constellation contributing to the mortality from PCa.
Notably, populations with low dairy protein intake like
the Inuit and Alaska native men exhibit an extremely
low incidence and mortality rate of PCa [28,29]. It is
alarming, that daily milk consumption in adolescence
has recently been associated with a 3.2-fold risk of
advanced PCa in adulthood [30]. Notably, milk and dairy
consumption has been linked to an increased incidence
of acne in adolescence [31-35]. Severe acne in adoles-
cence has been related to an increased risk of PCa in
adulthood [36]. The association between PCa and acne
might already point to overstimulated mTORC1-ny. Cheese is a rich source of the mTORC1-activating amino acid
like Germany.
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and prostate gland during puberty as the underlying
common cause of aberrant signal transduction [37].
As the majority of controlled studies have shown a
dose-related association between dairy protein intake
and increased risk of PCa, the underlying mechanism of
dairy-induced PCa has not yet been identified. The cal-
cium hypothesis [9,38], however, does not explain the
cancer promoting effects of dairy protein intake as non-
dairy-derived calcium showed no relation to an
increased risk of PCa [10]. Neither intake of calcium
from dairy products nor calcium supplements were asso-
ciated with PCa risk in a prospective study of Koh et al.
[39]. Neither high calcium nor high phosphate intake of
dairy products have been shown to change intracellular
concentrations of 1,25(OH)2D in PCa cells. Intracellular
1,25(OH)2D concentrations are primarily regulated by
intracellular synthesis and not by 1,25(OH)2D uptake
from the circulation [12]. Thus, neither the calcium hy-
pothesis [38] nor the phosphorus hypothesis of PCa [40]
provide reasonable tumorigenic mechanisms compatible
with recent insights into the molecular biology of vita-
min D, which could explain the proliferative cellular
effects of dairy intake, thus calling both hypotheses of
PCa into question. It is the major purpose of this paper
to provide evidence that dairy protein-derived amino
acids provide the cancer-promoting effect of dairy by
introducing mammalian milk as a fundamental growth-
promoting mTORC1-signaling system of mammalian
evolution.
Evidence for cows´milk growth-stimulatory effects on
prostate cancer
Organic cows' milk, digested in vitro, stimulated the
growth of LNCaP prostate cancer cells in each of 14
separate experiments, producing an average increase in
growth rate of over 30% [41]. Remarkably, isolated
addition of digested purified casein had a less stimula-
tory effect on LNCaP cell proliferation than whole cow´
s milk [41]. This observation implies that the hormonal
compounds of commercial cows milk like estrogens and
IGF-1 are not the exclusive stimuli of milk-induced
PCa cell growth, but rather points to the role of amino
acids derived from hydrolysed milk proteins. This
in vitro evidence fits well with recent epidemiological
data from a cohort of 3,918 men diagnosed with appar-
ently localized PCa. In this cohort, high versus low
intakes of whole milk substantially increased the risk of
PCa progression [42]. To understand the biological im-
pact of milk in prostate tumorigenesis, the signal trans-
duction pathways driven by mammalian milk, an
mTORC1-signaling system naturally confined to the
neonatal growth period, must be examined in greater
detail.mTORC1: the convergence point of nutrient-derived and
milk-mediated signaling
Milk signaling is integrated and mediated by the nutrient-
sensitive kinase mTORC1 (mammalian target of rapamy-
cin complex 1). mTORC1 links amino acid, growth factor,
and energy availability to prostate epithelial cell growth,
proliferation, motility, autophagy, morphogenesis and
tumorigenesis. The mTORC1 signaling pathway has be-
come a major focus of human cancer research [43]. It is
thus of utmost importance to understand the nutrient-
mediated signaling pathways regulating mTORC1, the
central hub controlling cell signaling, cell growth and cell
proliferation.
mTORC1 signaling stimulates gene transcription,
translation, ribosome biogenesis, protein synthesis, insu-
lin synthesis, cell growth, cell proliferation, lipid synthe-
sis but suppresses mechanisms of autophagy [44-49].
mTOR is a multi-domain protein of approximately
300 kDa exhibiting a protein kinase domain at its
C-terminus related to phosphoinositol-3-kinases (PI3Ks).
In mammalian cells two functionally different mTOR
complexes exist: mTORC1 and mTORC2. Among other
functional proteins, mTORC1 contains the important
partner protein Raptor, which interacts with substrates
for mTORC1-mediated phosphorylation like p70 S6 kin-
ase 1 (S6K1). mTORC1 controls the impact of nutrient-
derived signals on the G1/S transition and G2/M pro-
gression of the cell cycle [46]. In contrast to mTORC2,
which contains the partner protein Rictor, only
mTORC1 plays a special role in sensing cellular nutri-
ents, amino acids, and energy (ATP) levels, which are
important stimuli for cell growth and proliferation. Liver
kinase B1 (LKB1) and AMP-activated protein kinase
(AMPK) are further critical regulators of mTORC1 [50].
Most functions of mTORC1 are inhibited by rapamycin,
a triene macrolide antibiotic synthesized by Streptomyces
hygroscopicus [51].
Pivotal role of the essential amino acid leucine for
mTORC1 activation
mTORC1 activation is critically dependent on the avail-
ability of sufficient amounts of amino acids, especially of
the branched-chain essential amino acid (BCAA) leucine
[52-54] (Figure 2). Recent advances in molecular biology
have elucidated two parallel mechanisms of mTORC1
activation: 1) the upstream activation of the small
GTPase Rheb (Ras homolog enriched in brain) by
growth factor signals (insulin, IGF-1, PDGF) and high
cellular energy levels (glucose, ATP), and 2) the amino
acid-dependent translocation of inactive mTORC1 to
active Rheb localized at late endosome or lysosome com-
partments [53-56] (Figure 2). The activity of Rheb is
tightly regulated by the tuberous sclerosis proteins TSC1
(hamartin) and TSC2 (tuberin), which form a functional
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Figure 2 Synopsis of major pathways activating mTORC1. mTORC1 is activated by leucine, insulin, IGF-1 and glucose. The activating signals
of the growth factors insulin and IGF-1 and the energy source glucose are mediated by attenuating the inhibitory function of TSC2 towards
Rheb. The key amino acid leucine activates mTORC1 independent of the TSC2 pathway. Leucine stimulates Rag GTPase-mediated translocation of
inactive mTORC1 to endosome/lysosome membranes enriched in activated Rheb. See list of abbreviations.
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sesses a GTPase-activating protein, which hydrolyses
GTP to GDP. The TSC1/TSC2 complex provides this
function to Rheb leading to inactivation of Rheb. In con-
trast, insulin and IGF-1, both activate the kinase Akt
(protein kinase B) as well as other growth-related
kinases such as ERK and RSK, which phosphorylate
TSC2 and thereby attenuate the inhibitory function of
the TSC1/TSC2 complex. This inhibition leads to activa-
tion of Rheb with final activation of mTORC1 [57-60]
(Figure 2).
Besides the important input of growth factor signaling
on mTORC1 activation, AMPK, an essential energy sen-
sor, plays a key role in energy-dependent mTORC1
regulation. During states of energy-deficient conditions
like glucose deprivation, ATP levels fall and AMP levelsrise, resulting in AMPK activation. AMPK phosphory-
lates TSC2 and Raptor, thereby suppressing mTORC1
activity [60,61]. Abundant cellular energy provided by
hypercaloric and high glycemic loads of Western diet
thus reduces AMPK activity and stimulates mTORC1
signaling. In Western diet hyperglycemic food com-
pounds are frequently combined with dairy products like
cornflakes with milk or pizza and burgers combined
with cheese.
Notably, leucine has been identified as the primarily
responsible branched-chain amino acid for mTORC1-
dependent stimulation of skeletal muscle protein synthe-
sis [52]. In fact, in response to amino acid depletion,
mTORC1 activity is rapidly abolished [62]. Amino acid
starvation impairs binding of mTORC1 to Rheb [63].
From all essential amino acids, leucine exerts the
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cent evidence has been provided that amino acids and
especially leucine promote the cellular translocation of
inactive mTORC1 to lysosomal compartments enriched
in activated Rheb [53,55]. This spatial regulation of in-
active mTORC1 by amino acids is mediated by an active
Rag heterodimer, which is of utmost biological import-
ance for amino acid sensing by mTORC1. Thus,
mTORC1 integrates not only growth factor and energy
derived signals towards Rheb, but requires a parallel sig-
nal input of leucine for final mTORC1 activation by
translocation of inactive mTORC1 to cell compartments
enriched in activated Rheb (Figure 2). These two inde-
pendent major pathways of mTORC1 activation explain
why either insulin and IGF-1 signaling or amino acid
signaling alone is not sufficient to reach maximal
mTORC1 activation. Insulin is not able to activate the
mTORC1 pathway when cells are deprived of amino
acids [64]. Indeed, both insulin- and amino acid signal-
ing are required for maximal mTORC1 activity [65]. Evi-
dence will be provided that only milk proteins in
comparison to meat and fish have the unique ability to
preferentially increase both the insulin/IGF-1 and the
leucine signaling pathways necessary for maximal
mTORC1 activation.
Growing cells and especially proliferating tumor cells
not only require increased amounts of amino acids and
protein but also high amounts of lipids to enlarge their
cellular membrane compartments. It is thus not surpris-
ing that the key transcription factor of lipid biosynthesis
SREBP-1 (sterol regulatory element binding protein-1) is
dependent on upstream activation of mTORC1 [66,67].
Oncogenic mTORC1-signaling in prostate cancer cells
Increased insulin, IGF-1 and especially leucine signaling
with activation of mTORC1 are not only a requirement
for physiological growth during the neonatal period and
puberty but play a pivotal role in the process of tumori-
genesis [43,68-74]. In addition to various other cancers,
signaling pathways that activate mTORC1 are frequently
deregulated in PCa [43,74,75]. mTORC1 is upregulated
nearly in 100% of advanced human PCa [76] (Figure 3).
Activation of mTORC1 is a central component down-
stream of the phosphatidyl-inositol-3-kinase (PI3K)/Akt
signaling cascade. Akt-mediated phosphorylation of
TSC2 prevents TSC1/TSC2 complex formation, which
drives the small GTPase Rheb into the GTP-bound ac-
tive state [77], leading to the phosphorylation and activa-
tion of mTORC1 at Ser2448 [78,79]. PTEN, phosphatase
and tensin homologue deleted on chromosome 10, is a
negative regulator of Akt activation, as it converts phos-
phatidylinositol 3,4,5-triphosphate [PtdIns(3,4,5)P3] back
to PtdIns(4,5)P2, leading to reduced recruitment of Akt
to the cell membrane, which is the important locationfor PDK-1-mediated final phosphorylation and full acti-
vation of Akt [80]. The PI3K/Akt/mTORC1-pathway is
aberrantly activated in the majority of PCa due to PTEN
copy number loss or loss of function of at least one
PTEN allele [75,76,81]. Genetic findings in mouse mod-
els implicate mTORC1 hyperactivation in both PCa ini-
tiation and progression [82-87]. It has recently been
reported that Rheb, the final upstream activator of
mTORC1, is amplified in human PCa [88]. In the mouse
prostate, Pten haploinsufficiency cooperates with Rheb-
overexpression and markedly promoted mTORC1-
mediated prostate tumorigenesis [88] (Figure 3). Com-
pelling evidence has recently demonstrated that
mTORC1 controls the translational program of mRNA
subsets of genes involved in PCa initiation, invasion and
metastasis [89-91].
Cross-talk between androgen receptor and mTOR in
prostate cancer
The two most frequently activated signaling pathways in
PCa are driven by androgen receptor (AR) and PI3K.
Genetic loss of either mTOR or Akt1 is sufficient to sig-
nifcantly reduce initiation of PCa in the conditional Pten
mouse model [90-92]. The allosteric mTORC1 inhibitor
rapamycin has been shown to revert Akt-dependent
early prostate intraepithelial neoplasia (PIN) in young
mice through regulation of apoptotic and HIF-1-
dependent pathways [93]. It has been shown in the pros-
tate-specific Pten-deleted mouse model of PCa that de-
pletion of androgens significantly inhibited tumor
growth progression without altering the activation of
Akt and mTOR, however, the combination of antiandro-
gen treatment with rapamycin-mediated mTORC1 in-
hibition exhibited additive antitumor effects [94]. Recent
evidence points to a reciprocal feedback regulation of
PI3K and AR singaling in PTEN-deficient PCa [95]. In
human and murine tumors with PTEN deletion inhib-
ition of the PI3K pathway promoted AR activity, whereas
androgen blockade activated Akt signaling [95]. Com-
bined PI3K and AR inhibition was superior to single
agent therapy in PTEN loss PCa [95].
Dihydrotestosterone (DHT)-stimulation of LNCaP
prostate cancer cells, which have constitutive PI3K/Akt
pathway activation due to loss of PTEN, caused
increased expression of cyclin D1, D2, and D3 proteins,
retinoblastoma protein hyperphosphorylation and cell
cycle progression [96]. DHT treatment increased
mTORC1 activity as assessed by phosphorylation of the
downstream targets S6K1 and 4EBP1. However,
mTORC1 inhibition with rapamycin blocked the DHT-
stimulated increase in cyclin D proteins [96]. mTORC1
activation by DHT was dependent on AR-stimulated
mRNA synthesis, including genes that regulate cellular
leucine availability [96]. L-type amino acid transporters
Figure 3 Aberrations of PI3K-Akt-mTORC1 signaling pathway in prostate cancer. Mutation-induced hyperactivated PI3K, Akt and
overexpression of Rheb stimulate mTORC1. Loss of PTEN results in hyperactive Akt signaling. Androgens activate Akt via mTORC2 and via
upregulation of L-type amino acid transporters (LAT) promote leucine-stimulated mTORC1 activation.
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amino acids, especially leucine, for leucine-mediated
mTORC1 signaling promoting cell growth and prolifera-
tion of PCa cells [97]. In the androgen-sensitive LNCaP
cell line, androgen-induced upregulation of LAT3 ex-
pression was related to increased leucine-mTORC1-
mediated tumor cell growth [97]. High levels of LAT3
were detected in primary disease, whereas increased
levels of LAT1 were observed after ADT and in meta-
static lesions [97]. It has recently been shown that
BCAA metabolism is affected by malignant progression
of PCa cells [98]. Androgens rapidly reduced the protein
concentration of the cell cycle inhibitor p27 in PCa cells
by increasing proteasome-mediated degradation of p27
[99]. Androgens increased mTORC2-mediated Akt
(S473) phosphorylation, which stimulated Akt-mediated
phosphorylation of p27(T157), the critical signal for p27
proteasomal degradation [99]. Furthermore, androgen-mTORC2-mediated activation of Akt resulted in
increased phosphorylation of FoxO1, which in its phos-
phorylated form is extruded from the nucleus into the
cytoplasm [99]. Activated Akt is part of the canonical
pathway activating mTORC1. Furthermore, cytoplasmic
FoxO1 has been shown to bind to the C-terminal se-
quence of TSC2, thereby disrupting the TSC1/TSC2
complex resulting in further activation of mTORC1
[100]. Moreover, androgen-mediated nuclear FoxO1 ex-
trusion resulted in diminished expression of the AMPK
activator Sestrin3, thus allowing further activation of
mTORC1 [101].
Recently, Hsieh et al. [91] have demonstrated that
complete mTOR inhibition by the ATP site inhibitor of
mTOR, INK128, prevented PCa invasion and metastasis
in vitro. Obviously, mutations or activating posttransla-
tional modifications of the upstream activators of
mTORC1 (Akt, PI3K, Rheb, and loss of PTEN function)
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(Figure 3), which drives the ´cancerous´ translation ma-
chinery steering cancer initiation, cancer invasion and
metastasis [91]. Thus, substantial evidence underlines
the pivotal role of exaggerated mTORC1 signaling in
both PCa development and progression. Continuously
increased mTORC1 signaling has been associated with
tumor initiation as well as tumor progression [91]. In
fact, sustained proliferative signaling has been identified
as a hallmark of cancer and comprises the most import-
ant biological capability during the multistep develop-
ment of human tumors [102].
Mammalian milk: an endocrine mTORC1 activating system
for neonatal growth
To understand the impact of dairy protein consumption
on PCa tumorigenesis, we have to appreciate the signal
transduction of mammalian milk. Although the growth-
stimulating effect of cow´s milk has been recognized
since 1928, from it´s effect on childhood stature, the
growth-promoting pathways of milk-derived signal
transduction have not been a matter of medical concern
[103]. There is substantial epidemiological evidence that
cow´s milk consumption increases linear growth and
body mass index in infants and accelerates the onset of
menarche [104-106]. The function of mammalian milk is
not only to provide sufficient calories and nutrients to
the newborn but in parallel to promote postnatal growth
by milk-mediated growth factor signaling. This over-
looked growth-promoting functionality of milk repre-
sents the fundamental obstacle, which for many decadesFigure 4 Milk signaling, prostate gland morphogenesis and tumorige
morphogenesis. B) Excessive cow´s milk signaling by infant formula feeding
adverse effects promoting prostate tumorigenesis.obscured the link between the growth-stimulating activ-
ity of cow´s milk and cow´s milk-mediated promotion of
cancer growth. To fulfill its biological function to pro-
mote growth and survival, milk enhances the activity of
mTORC1 by increasing 1) insulin/IGF-1 signaling lead-
ing to activation of Rheb, and 2) by providing substantial
amounts of the essential BCAAs like leucine, which
stimulate amino acid-mediated mTORC1 activation.
Differences in the magnitude of mTORC1 signaling of
cow´s milk versus human milk
For adequate species-specific growth requirements, each
mammalian species has developed its own species-specific
magnitude of milk-mediated mTORC1 signaling. The
strength of mTORC1-mediated stimulation of mammalian
growth is associated with the total protein and total leu-
cine concentration in mammalian milk [107]. The milk of
various mammalian species shows significant species-
dependent variations in the concentration of total milk
protein. However, milk of all mammals exhibit a constant
ratio of 0,1 g of leucine per 1 g of total milk protein [108].
Remarkably, species with the highest milk protein con-
centration exhibit the most rapid growth rate. An in-
verse relation exists between the protein plus leucine
content of mammalian milk and the neonate´s rate of
birth weight duplication [107]. For instance, the leucine
content of rat´s milk is 11 g/L, of cat´s milk 8,9 g/L, of
cow´s milk 3,3 g/L , and of human milk 0,9 g/L, respect-
ively [108]. The rat doubles birth weight already after
4 days, the cat after 10 days, the calf after 40 days, and
the human neonate, the mammal with the slowestnesis. A) Signaling of human milk and physiological prostate
disturbing regular prostate morphogenesis resulting in long-term
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data imply, that the leucine-mTORC1 signaling axis of
cow´s milk is much higher than that of human milk, as
cow´s milk contains threefold the amount of total pro-
tein and total leucine in comparison to human milk
[107,108]. Moreover, the weight gain of calves during
the first year of cow´s milk feeding (0.7-0.8 kg/day) is
nearly 40-times higher than that of breast-fed human
infants (0.02 kg/day) [109]. It has been demonstrated
that cow´s milk-based infant formula feeding signifi-
cantly increases serum concentrations of leucine, insu-
lin, and IGF-1 in comparison to physiological breast-
feeding [110,111] (Figure 4). Thus, cow´s milk-based in-
fant formula feeding induces higher magnitudes of
mTORC1 signaling in comparison to natural breast-
feeding of human milk [112,113]. The great differences
in the magnitude of mTORC1 signaling may explain the
differences in growth velocity and weight gain between
Bos taurus and Homo sapiens. Moreover, the relatively
low mTORC1 signaling axis of human neonates in com-
parison to Bos taurus allows a slower rate of brain
growth permitting more time for the accumulation of
long-chain omega-6 polyunsaturated fatty acids (specif-
ically 20:4n6) and long-chain omega-3 polyunsaturated
fatty acids (specifically 22:6n3), critical nutrients for the
development of complex brain functions, an evolution-
ary advantage of Homo sapiens [114]. With regard to
mTORC1-dependent postnatal events in prostate mor-
phogenesis and prostate gland development it is of spe-
cial concern that infant formula feeding in comparison
to natural breast-feeding may over-stimulate mTORC1
signaling thereby disturbing physiological conditions of
prostate growth and development during the postnatal
period.
Cow´s milk protein elevates IGF-1 serum levels: a known
risk factor of prostate cancer
Insulin-like growth factor-1 (IGF-1) is an important acti-
vator of PI3K/Akt signaling resulting in mTORC1 acti-
vation [57,60,68]. It has been demonstrated in rat
hepatocyte primary cultures that hepatic IGF-1 gene
expression directly depends upon the availability of es-
sential amino acids [115]. Elevated IGF-1 serum concen-
trations are associated with consumption of animal
versus vegetable proteins. In comparison to meat protein
increased intake of milk protein by milk consumption
from 200 to 600 ml resulted in a 30% increase in IGF-1
serum concentrations [116]. Furthermore, skim milk
protein versus meat intake increased serum IGF-1 con-
centrations in 8-year-old boys [117], underlining the
higher IGF-1-enhancing activity of milk proteins in com-
parison to meat protein. In prepubertal boys, casein ver-
sus whey protein elicited a greater rise in plasma IGF-1
concentrations, whereas whey protein versus caseinelicited a greater rise in postprandial insulin plasma con-
centrations [118]. Thus, there is substantial evidence in
humans, that cow´s milk protein intake in comparison
to meat protein exerts stronger effects on protein-
induced IGF-1 signaling. Therefore, it is reasonable to
differentiate between signaling proteins like milk proteins
and structural proteins like meat and fish protein, which
are less efficient in elevating insulin and IGF-1 plasma
concentrations than milk proteins.
Lower IGF-1 signaling due to mutations with reduced
activity of the IGF-1 receptor are associated with longev-
ity and lower incidence rates of cancer [119]. Moreover,
congenital IGF-1 deficiency has been shown to confer
protection against the development of malignancies in
humans including a lower prevalence of PCa [120]. In a
cohort of 99 untreated individuals with Laron syndrome,
who exhibit growth hormone receptor mutations with
congenital IGF-1 deficiency, only one nonlethal malig-
nancy has been detected after 22 years of monitoring,
whereas not affected relatives exhibited a cancer preva-
lence of 17% with PCa being the third most common
cancer in this control population [121]. Cells cultured
with IGF-1-deficient serum of Laron individuals showed
a 20% reduction of TOR expression and exhibited
increased activity of nuclear FoxO protein levels [122].
Thus, low IGF-1 serum levels attenuated IGF-1/
mTORC1-mediated cell proliferation and increased
FoxO-mediated anti-oxidative responses by upregulation
of superoxide dismutase and catalase as well as by
FoxO-driven pro-apoptotic responses, all of which are
most important cancer-preventive mechanisms [122]. In
accordance with observed cancer-protective effects of
low IGF-1 signaling is a recent epidemiological study,
which demonstrated that high serum IGF-1 concentra-
tions were associated with increased cancer deaths in
older men [123]. Notably, men with type 2 diabetes were
found to have a lower incidence of PCa, presumably due
to decreased IGF-1 serum levels [124]. However, recent
large cohort studies have reported the association of type
2 diabetes with advanced high-grade PCa [125]. Data
from meta-regression analyses of case control studies
have provided substantial evidence that high serum con-
centrations of insulin and IGF-1 are associated with
increased risk of PCa [126-128]. Increased serum con-
centrations of IGF-1 are specifically involved in the early
pathogenesis of PCa [126]. The European Prospective
Investigation into Cancer and Nutrition clearly confirmed
the correlation between increased dairy protein con-
sumption and raised IGF-1 serum concentrations in
adults [129,130]. A recent cross-sectional analysis using
data of 1,798 men in the UK demonstrated that for one
standard deviation increase in dairy protein intake, IGF-1
increased by 6.02 ng/ml [131]. Among other animal- and
plant-derived proteins, dairy protein was most strongly
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[131]. Notably, low versus high meat intake was not asso-
ciated with a change of IGF-1 serum levels [131]. These
data strongly imply, that the increase of serum IGF-1
concentrations by cow´s milk protein consumption may
result in elevated IGF-1-driven mTORC1 signaling, the
driving mechanism promoting the initiation and progres-
sion of PCa.
Cow´s milk protein intake increases postprandial serum
insulin levels
Insulin, like IGF-1, is a growth hormone, which activates
insulin receptor as well as IGF-1 receptor signaling and
stimulates the activity of mTORC1 [68,132]. As it is the
biological function of mammalian milk to promote
growth, milk performs its mission by increasing the
serum concentrations of both growth hormones insulin
and IGF-1. Cow´s milk proteins, which are absent in
Paleolithic diets and traditional diets of Southeast Asia,
significantly contribute to higher insulin/IGF-1 signaling
of Western diet [133]. Mammalian milk upregulates insu-
lin secretion of pancreatic β-cells as well as IGF-1 synthe-
sis by the liver (Figure 4). BCAAs, predominantly leucine,
stimulate β-cell mTORC1 resulting in increased insulin
secretion [134-137]. Moreover, milk consumption not
only activates the somatotropic axis but also the entero-
insular axis by stimulating intestinal incretin secretion of
glucose-dependent insulinotropic polypeptide (GIP),
which further augments insulin secretion [138,139].
Milk´s excessive insulinotropic activity is well character-
ized by cow milk´s high insulinemic index [140].
It has recently been confirmed that BCAA-enriched
postprandial serum after ingestion of whey protein by
healthy individuals significantly induced insulin secretion
of isolated mouse pancreatic islets [141]. The insulino-
genic effect of whey protein was predominantly mediated
by the whey protein-derived amino acids leucine, isoleu-
cine, valine, lysine and threonine and was augmented by
increased intestinal release of GIP [141]. Casein protein
hydrolysate and leucine co-ingestion in patients with
type 2 diabetes stimulated postprandial insulin secretion
[142]. Notably, increased daily intake of milk but not
meat significantly elevated fasting insulin and IGF-1
serum concentrations and increased insulin resistance in
8-year old boys [117,143]. Milk-induced insulin resist-
ance can be well explained by increased mTORC1-
mediated activation of S6K1. Insulin receptor substrate-1
(IRS-1) is an important target of S6K1 phosphorylation,
which inhibits downstream insulin signaling in adipose
tissue, liver and skeletal muscle [144] (Figure 2).
In accordance with epidemiological evidence, an
association of diet-induced hyper-insulinemia with accel-
erated growth of LNCaP xenografts has been reported
[145]. Moreover, the insulin-analogues glargine anddetemir exhibited IGF-1-like mitogenic and anti-apop-
totic activities in cultured PC-3 prostate cancer cells
[146]. In contrast, reduced circulating IGF-1 levels
obtained by calorie restriction attenuated mTORC1 sig-
naling and inhibited tumorigenesis [147]. Dietary restric-
tion in mice resulted in reduced IGF-1 serum
concentrations and decreased mTORC1 activity in the
dorsolateral prostate of mice [148]. Recent evidence sup-
ports a “higher-level” interaction between AR signaling
and IGF-1 signaling via recruitment of direct pathways
toward activation, transcriptional regulation, and protein
posttranslational changes, all critical to PCa cell survival
[149]. The reduction in high protein intake commonly
provided by Western diet has been proposed as an im-
portant strategy for dietary anti-cancer interventions
[150]. However, the quantity and quality of protein intake
has been recognized as the key determinant of circulating
IGF-1 concentrations and postprandial hyperinsulinemia.
Milk (insulinemic index > 100) and especially the whey
proteins are highly insulinotropic in comparison to meat
(insulinemic index 51) [140]. Moreover, total protein in-
take is not the most important determinant controlling
high IGF-1 serum concentrations as milk protein induces
higher IGF-1 concentrations than meat. Thus, for under-
standing the role of nutrient signaling in cancer biology it
appears to be of pivotal importance not only to consider
total daily protein intake but rather to differentiate be-
tween the intake of BCAA-enriched signaling proteins
(derived primarily from milk) and the intake of less insu-
linotropic structural proteins (primarily derived from
meat and fish).
Whey protein ingestion activates mTORC1 signaling
There is yet no direct experimental evidence for the acti-
vation of mTORC1 in prostate epithelial cells after cow´s
milk protein consumption. However, it has been convin-
cingly demonstrated that a single dose (26.6 g) of whey
protein isolate in young men immediately after a resist-
ance exercise significantly increased mTORC1 signaling
in skeletal muscle (vastus lateralis) 2 h post-exercise
[151]. Whey protein intake significantly enhanced the
phosphorylation of mTOR(Ser2448), 4EBP1(Thr37/46)
and S6K1(Thr389) at 2 h post-exercise [151]. These data
are in agreement with studies in rat skeletal muscle,
which have demonstrated a dose-response between leu-
cine ingestion and increased S6K1(Thr389) phosphoryl-
ation [152]. In addition to S6K1 phosphorylation, the
phosphorylation of 4EBP1 is also sensitive to amino acid
provision [153], and the site-specific phosphorylation of
Thr37/46 is reported to be crucial for optimal activation
of 4EBP1 [154]. These data of whey protein-induced
mTORC1 activation in muscle cells are most likely con-
ferrable to other human tissues like the prostate gland
and support the role of dairy protein-induced mTORC1
Table 1 Comparison of leucine-insulin-IGF-1-signaling
between dairy-derived signaling proteins versus meat-
derived structural proteins [116-118]
Protein source Leucine Insulin IGF-1
Whey """ """
Casein "" """
Milk protein "" " """
Meat protein "" " "
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malian milk to promote growth.
Milk-mediated mTORC1 signaling amplifies oncogenic
mTORC1 signaling
Most importantly, to achieve the physiological require-
ments for adequate growth, milk proteins provide the
highest amounts of leucine and the most effective
BCAAs required for mTORC1 activation [48,51,52,62].
Whey proteins have to be regarded as unique life starter
proteins that contain the highest amount of leucine
(14%), followed by casein (10%), the major protein con-
stituent of cow´s milk and cheese [155]. Since mTORC1
signaling positively regulates protein synthesis and ribo-
some biogenesis, both of which require amino acids, it
makes physiologically sense that mTORC1 signaling is
highly dependent upon amino acid availability. With-
drawal of leucine has been shown to be nearly as effective
in down-regulation of mTORC1 signaling as withdrawal
of all amino acids [52,62]. Moreover, the preeminent ef-
fect of leucine withdrawal has been consistently observed
in a variety of cell types, thus underlining the primacy of
leucine in amino acid-mediated mTORC1 regulation
[47-49].
It is important to realize that milk protein intake
appears to be more efficient in activating mTORC1 than
meat or cheese protein consumption as milk contains
the highly water soluble and easily hydrolysable leucine-
rich whey proteins, which are responsible for the rapid
and elevated postprandial rise in plasma leucine concen-
trations [139,141]. These whey protein-mediated high
pulsatile elevations of plasma leucine- and GIP concen-
trations may explain the high insulinemic index of milk
and other whey protein-containing milk products like
yoghurt (insulinemic index of 89-115) in comparison to
energy-equivalent protein uptakes of beef (insulinemic
index of 51) and cheese (insulinemic index of 45) [156].
In comparison to meat, intake of milk and whey protein-
comprising milk products thus results in higher and
more rapid increases of leucine and insulin signals, which
are both important downstream activators of mTORC1.
As signal transduction in biological systems is known to
respond more efficiently to sudden increases of incoming
signals (Δ signal) than to prolonged exposures of high
signal levels, the pronounced differences in the leucine-
mTORC1-insulin kinetics between whey protein and
meat may explain why Paleolithic type diets are less insu-
linotropic and presumably less effective in mTORC1
stimulation than whey protein-accentuated Western
diets [157]. Previously, the growth-promoting effects of
milk consumption was explained exclusively by milk´s
ability to induce higher plasma concentrations of IGF-1
while ignoring the co-stimulatory effects of leucine, insu-
lin, and IGF-1 signaling, all of which are finally integratedby the central regulator mTORC1 [158]. In this regard,
meat and fish protein consumption, in comparison to
whey protein-enriched dairy products, may exert less
oncogenic stimulation. Circulating pulsatile rises of leu-
cine and insulin concentrations together with permanently
elevated serum concentrations of IGF-1 may be respon-
sible for cow milk´s optimized mode of hyperactivated
mTORC1 signaling, which promotes growth stimulation
of prostate epithelial cells and further amplifies already
upregulated oncogenic mTORC1 signaling of PCa cells
with preexisting alterations of cell growth-promoting sig-
naling pathways (Table 1; Figure 4B).BCAA and leucine overload by dairy protein-rich
Western diet
A worldwide continuous increase of dairy protein con-
sumption has occurred in Western countries, as exem-
plified by the annual increase of cheese consumption per
capita in the Federal Republic of Germany from 3.9 kg
in 1935 to 23.0 kg in 2011 (Figure 1) [112]. The high
BCAA and leucine content of animal protein-rich West-
ern diet strongly contrasts to the low dietary leucine
amounts in traditional Asian diets because of their high
reliance upon plant proteins, containing little leucine.
Thus, during the last five decades a steady increase in
total leucine intake in westernized countries has
occurred as exemplified by the German per capita leu-
cine consumption (Table 2). The abundant cheese con-
sumption in Western countries substantially contributed
to the increased total leucine intake, which has been
recognized as an important activating signal of mTORC1
and may explain the association between cheese con-
sumption and increased risk of PCa [6]. For example,
the leucine content of 100 g of Gouda cheese (2.4 g leu-
cine) is considerably higher than that of 100 g white cab-
bage (0.056 g), or 100 g apple (0.016 g). To reach the
leucine content provided by 100 g Gouda cheese, 4.2 kg
of white cabbage or 100 apples would have to be con-
sumed [112]. Cheese is widely consumed with fast food
products like pizza, tacos and cheeseburgers. The abun-
dance of leucine in the Western diet and especially the
combination of easily releasable leucine from whey pro-
teins in combination with high glycemic load foods may
Table 2 Annual animal protein-derived per capita leucine
intake in Germany
Animal protein [g/y] 1950/51 1974/75 2007/08
Total meat (21 g Leucine/kg) 552 1 172 1 268
Egg/egg products (13 g Leucine/kg)98 225 169
Fish (19 g Leucine/kg) 131 78 143
Cheese (25 g Leucine/kg) 96 293 558
Average total per capita leucine
uptake [g/y]
877 (100%)1768 (199%)2138 (241%)
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The introduction of widespread refrigeration technology
since the 1950s in industrialized countries has allowed
for the increased and persistent availability of dairy
proteins.Commercial cow´s milk: a source of dietary estrogens
There is recent concern that not only androgens, but also
estrogens promote PCa [159]. Commercialized milk pro-
duction by pregnant cows releases uncontrolled amounts
of bovine steroids into the human food chain. PCa cells
express estrogen receptors (ERs). ADT has been shown to
upregulate stromal ERs [160]. The addition of estradiol
(10-8 M) significantly promoted growth of LNCaP cells
in vitro [41]. In industrialized countries, a significant per-
centage of commercial milk comes from pregnant cows
containing elevated concentrations of estrogens and pro-
gesterone [161-164], which may synergistically enhance
mTORC1 signaling. 5α-Pregnanedione, a steroid com-
pound of commercial cow´s milk, is a direct precursor of
DHT and may act through mTORC2-Akt as well as AR-
LAT3-leucine-mediated activation mTORC1 in prostate
tumorigenesis (Figure 5). Even more evidence underlines
the role of estrogens in prostate tumorigenesis [165,166].
Animal and limited human studies suggest that estrogens
are involved in prostate carcinogenesis by genotoxic
mechanisms [166]. 17β-estradiol, which is generated from
testosterone by the enzyme aromatase, can be converted
to catecholestrogens, which through redox cycling may
generate reactive metabolites that can adduct to DNA and
potentially lead to mutations [166]. Furthermore, develop-
mental studies of prostate morphogenesis demonstrated a
critical time for estrogen action during the development
of the prostatic tissue [165]. It has been suggested that es-
trogen-sensitive cells may remain in the prostate and be
more responsive to estrogens later in life or be less re-
sponsive to the normal controlling mechanisms of pros-
tatic growth [165]. Dogs as with men are able to develop
PCa. Marked prostate hyperplasia has been induced in
dogs especially by combined administration of DHT with
estrogens [167,168].In the prostate, ER-β is preferentially expressed in
epithelial cells but ER-α is found in stromal and basal
cells [169]. There is evidence for increased ER staining
intensity in malignant prostates [170]. Recently, ER-β
expression has been detected in PCa cells [171]. Not-
ably, in the human breast cancer MCF-7 cell line, 17β-
estradiol stimulated leucine uptake by increasing the
expression of LAT1 [172]. Although no data are yet
available on estrogen-mediated leucine uptake in PCa
cells, it is conceivable that commercial milk-derived
estrogens may further augment leucine-mTORC1-
signaling of PCa cells. Remarkably, cow´s milk feeding to
female rats with chemically dimethylbenz (a) anthracene
(DMBA)-induced mammary cancer in comparison to
milk-free controls promoted the growth of mammary
tumors and doubled the number and volume of tumor
cells [173,174]. Moreover, commercial cow´s milk was
found to be uterotrophic in rats [175], which represents
more evidence of milk´s estrogenic and pro-proliferative
activity. Remarkably, 17β-estradiol stimulated leucine
uptake by MCF-7 breast cancer cells, which appear to
increase leucine uptake predominately by LAT1 [172].
PCa cells coordinate the expression of L-type amino
acid transporters such as LAT1 and LAT3 to maintain
sufficient levels of leucine needed for mTORC1 signal-
ing and cell growth [97]. Noteworthy, the mTORC1 in-
hibitor rapamycin inhibited the proliferation of ER-
positive breast cancer cells [176]. These animal studies
and one human intervention study [164] strongly sug-
gest that commercial cow´s milk (especially if it is
derived from pregnant cows) contains estrogen metabo-
lites with significant oral bioavailability. This observa-
tion is further supported by evidence showing that the
most prevalent form of estrogen in cow´s milk is es-
trone sulfate [159], which coincidentally comprises al-
most half of the conjugated estrogens in the most
frequently prescribed oral hormone replacement ther-
apies for menopausal women.
It should be realized that low fat (skim milk) was
as effective in mammary tumor promotion as whole
milk [173,174]. Although it is well known that the
lipid soluble steroids of milk are mainly distributed
within milk´s fat fraction, conjugated estrogens have
been found in high amounts in skim milk [162]. In
fact, several studies emphasized a stronger association
of PCa with the consumption of low fat/nonfat milk
than with whole milk [16,18,19]. Hence, it is conceiv-
able that the protein fraction of milk may act syner-
gistically with conjugated estrogens present in
commercial skim milk in the promotion of prostate
tumorigenesis.
Moreover, Ganmaa et al. [6] provided evidence that
the combination of “milk + cheese” was associated with
increased risk of PCa mortality, a combination that is
Figure 5 Boostering effects of cow´s milk consumption on prostate cancer-associated high mTORC1 signaling. Milk and dairy protein
consumption increase serum insulin and IGF-1 concentrations and provide abundant leucine for mTORC1 activation. Milk-derived estrogens and
androgen-precursors from pregnant* cows augment LAT-mediated leucine uptake promoting further mTORC1 activation. Milk signaling
shares common pathways of PCa with hyperactivated mTORC1 signaling due to cancer-associated alterations of Akt, PI3K, PTEN and Rheb
(labeled in red).
Melnik et al. Nutrition & Metabolism 2012, 9:74 Page 12 of 24
http://www.nutritionandmetabolism.com/content/9/1/74subsumed as “total dairy” in various studies [10].
Cheese consumption is a major dietary source of milk
fat, which is contaminated by pregnancy-derived bo-
vine estrogen metabolites in free and conjugated forms
[161,162]. Excessive cheese consumption derived from
commercial milk of pregnant cows thus provides an
undesirable estrogen load, which may synergistically
amplify the intrinsic growth promoting effects of milk
proteins. Hence, substantial evidence supports the
view that milk signaling shares synergistic effects
with oncogenic mTORC1 signaling pathways of PCa.
Commercial milk intake by increasing plasma con-
centrations of insulin, IGF-1, leucine, estrogens and
androgen-precursors may amplify preexistent high
mTORC1 signaling due to genetic alterations of the
PI3K/PTEN/Akt/Rheb/mTORC1 pathway of PCa cells
(Figure 5).Obesity, insulin resistance and increased mTORC-1
signaling and prostate cancer
Increased cow´s milk signaling via insulin, IGF-1 and
leucine has recently been linked to dysregulated early
metabolic programming and early promotion of
mTORC1-mediated adipogenesis [112,113]. More evi-
dence supports the influence of diet and obesity on
prostate health [177]. However, only an overall weak as-
sociation of PCa risk with obesity has been reported
[178,179]. Nevertheless, obesity appears to be associated
with more advanced, higher-grade disease and PCa mor-
tality [179-181]. Indeed, a relationship between BMI and
advanced PCa has been established [181,182]. Higher
milk consumption in children has been associated with
increased BMI [105]. It has been recognized that leucine
mediates mTORC1 signaling of adipocytes and plays a
crucial role in adipogenesis, adipogenic action of PPARγ
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189]. Moreover, leucine-stimulated mTORC1-S6K1 sig-
naling has been shown to play an important role in the
induction of insulin resistance [144,190] (Figure 2). In
humans, insulin resistance was induced by infusion
of high concentrations of amino acids, whereas the
mTORC1 inhibitor rapamycin improved insulin action
[191]. Infusion of an amino acid mixture to healthy men
resulted in elevation of plasma amino acids, hyperinsuli-
nemia and marked activation of S6K1 with increased in-
hibitory IRS-1 phosphorylation [192] (Figure 2). In
comparison to normal subjects, oral doses of leucine
(0,2 g/kg) stimulated exaggerated insulin release and
induced basal hyperinsulinemia in obese patients [193].
Notably, milk consumption in prepubertal boys has
been shown to increase serum insulin concentrations
associated with the induction of insulin resistance [143].
The resulting hyperleucinemia and hyperinsulinemia
may exert leucine- and insulin-mediated stimulatory
effects of prostate mTORC1 signaling. In fact, insulin as
well as hyperinsulinemic rat serum after generation of
high fat diet-induced insulin resistance promoted growth
of androgen-independent prostate cancer PC-3 cells
[194]. Furthermore, obesity-related higher concentra-
tions of circulating estrogens in synergy with commer-
cial milk-derived estrogens may stimulate leucine uptake
of prostate cells thus orchestrating a pro-proliferative
metabolic environment enhancing mTORC1 signaling.
Moreover, obesity-induced insulin resistance is not only
a proliferative risk constellation mediated by hyperinsuli-
nemia but is also associated with elevations in BCAAs
including leucine [195,196]. In obesity, adipose tissue
down-regulates BCAA uptake and metabolism resulting
in elevated concentrations of circulating BCAAs
[197,198]. In obesity and states of insulin resistance, ele-
vated BCAA have been associated with reduced expres-
sion of two adipose tissue BCAA catalytic enzymes:
mitochondrial branched-chain aminotransferase 2
(BCAT2) and branched-chain α-keto acid dehydrogenase
(BCKD E1α subunit) complex [197-199]. Thus, high
milk and dairy protein consumption in obese men may
have additive effects on already elevated obesity-derived
leucine levels, which may further enhance mTORC1 ac-
tivity of prostate epithelial cells and PCa cells.
Androgen deprivation therapy down-regulates
LAT3-mediated leucine uptake
PCa cells coordinate the expression of cellular amino
acid transporters LAT1 and LAT3 to maintain sufficient
levels of leucine required for mTORC1 signaling and cell
growth [97]. ADT downregulates AR-mediated expres-
sion of LAT3, which is important to maintain intracellu-
lar leucine levels for mTORC1 activation. Low levels of
intracellular leucine activate the translation of thetranscription factor ATF4, which initiates the transcrip-
tion of LAT1 to restore leucine-mediated mTORC1 sig-
naling [97]. Inhibition of either LAT3 or LAT1 can lead
to decreased growth of PCa cells [97]. Thus, it is con-
ceivable, that the total dietary leucine influx as wells as
androgen- and estrogen-regulated intracellular leucine-
uptake mechanisms play important roles for the regula-
tion of leucine-mediated mTORC1 signaling. These
findings suggest that preliminary therapeutic responses
to ADT may be related to attenuation of androgen-
dependent leucine-mediated activation of mTORC1 [97],
a therapeutic mechanism, which may be counterbalanced
by high intake of commercial cow´s milk protein.
Leucine and mTORC1-dependent inhibition of autophagy
Autophagy is an evolutionarily conserved catabolic path-
way that has multiple roles in carcinogenesis and cancer
therapy [200]. Autophagy can inhibit the initiation of
tumorigenesis through limiting cytoplasmic damage,
genomic instability and inflammation. Loss of certain
autophagic genes can lead to cancer [200]. Autophagy is
connected to major cancer networks and is predomin-
ately regulated by the activity of the mTORC1 pathway
[200]. Pathway enrichment analyses recently revealed
that mTORC1 and insulin signaling pathways are im-
portant in the regulation of genes involved in autophagy
[201]. Aberrant autophagy has been implicated to play
a major role in tumorigenesis [202,203]. Activated
mTORC1 stimulates cell growth and cell proliferation,
whereas suppression of mTORC1 activates autophagy
[204]. Autophagy is an important catabolic process in-
volving lysosomal turnover of proteins and organelles
for maintenance of cellular homeostasis and mitigation
of metabolic stress. Autophagy defects are linked to
aging and cancer. Autophagy is often impaired in human
PCa due to either activation of the PI3K/Akt/mTORC1
pathway, which inhibits autophagy, or through allelic
loss of the essential autophagy gene beclin 1 [205-207].
ADT induces apoptosis, as well as autophagy in andro-
gen-responsive PCa cells [208]. Amino acids and leucine
in particular are involved in the regulation of autophago-
some formation [209]. Emerging evidence has linked
leucine deprivation-induced protein breakdown to autop-
hagy. It has recently been shown, that leucine inhibits
autophagy in an mTORC1-dependent manner [210]. It is
conceivable that a high dietary influx of leucine may ad-
versely affect autophagy regulation in prostate epithelial
cells. Impaired autophagy regulation of prostate epithelial
cells and PCa cells by high dairy protein consumption
may thus further promote tumorigenesis and may aug-
ment aggressive transformation of PCa cells, especially in
those PCa cells exhibiting an allelic loss of beclin-1. It
has been shown that mTORC1 inhibition by rapamycin
induced autophagy and radiosensitized PTEN null PCa
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pound monascuspiloin in combination with ionizing ra-
diation has been shown to induce autophagy in PC-3
cells by inhibition of Akt/mTORC1 signaling [212]. In
contrast, milk-stimulated anabolic and pro-survival
mTORC1 signaling impairs the appropiate mTORC1 bal-
ance for maintaining sufficient autophagy and may at-
tenuate autophagy-inducing therapeutic strategies to kill
tumor cells. A persistent impairment of the appropriate
autophagy balance by continued cow´s milk-activated
mTORC1 signaling may thus contribute to the initiation
of tumorigenesis because reduced autophagy leads to de-
ficient clearance of cells with acquired DNA damage and
genetic instability [200]. In this regard, persistent cow´s
milk consumption with accelerated mTORC1 signaling
may not only contribute to the progression of already
established tumor cells but may promote the initiation
steps of prostate tumorigenesis.Glucocorticoids inhibit mTORC1 signaling and promote
autophagy and tissue atrophy
It has been demonstrated that dexamethasone treatment
decreased epithelial cell proliferation of the rat ventral
prostate and reduced mTOR signaling [213]. Recently, the
molecular crosstalk between glucocorticoid receptor (GR)
and mTORC1 signaling has been elaborated [214]. A well
known adverse effect of prolonged systemic glucocorticoid
treatment is tissue atrophy, the result of increased cellular
autophagy. In skeletal muscle, direct target genes of GR
signaling involve the protein REDD1 (regulated in devel-
opment and DNA damage responses) and the transcrip-
tion factor KLF15 (Krüppel-like factor-15). Both inhibit
mTORC1 activity, although via distinct mechanisms.
The REDD1 gene is activated at the promoter level
by ligand-bound GR and is transcriptionally induced
under stress conditions like hypoxia (via HIF1α),
which appears necessary for the downregulation of
mTORC1 signaling during stress conditions [215].
REDD1 functions upstream of TSC2 and Rheb in
order to downregulate mTORC1 signaling in response
to glucocorticosteroids [215-217].
KLF15 upregulates gene expression of BCAT2, a
mitochondrial enzyme, catalyzing the first step in the
catabolism of BCAAs to accelerate BCAA degradation
[218]. The glucocorticoid-driven GR-KLF15-BCAT2
axis may negatively modulate the intracellular avail-
ability of BCAAs resulting in a negative impact on
mTORC1 function in skeletal muscle. Glucocorticoid-
mediated downregulation of mTORC1 is not only a
superb explanation for glucocorticoid-induced muscle
atrophy, but also for the observed inhibitory effects
on epithelial cell proliferation of the prostate of
glucocorticoid-treated rats [213].Metformin antagonizes leucine-mediated mTORC1
signaling
Recent evidence points to cancer preventive and anti-
neoplastic activities of the anti-diabetic drug metformin
in PCa [219]. Currie et al. [220] reported that PCa mor-
tality, which is increased in patients with type 2 diabetes,
was reduced by metformin monotherapy in comparison
to monotherapy with sulfonylureas or insulin. Metfor-
min has been associated with improved overall survival
of diabetic PCa patients [221]. Available data support
the potential dual benefit of metformin on ADT-induced
metabolic syndrome and its antineoplastic activity in
PCa [222]. Metformin induced an up to 50% decrease in
cell viability in human PCa cell lines (DU145, PC-3, and
LNCaP) compared with only a modest effect (20% de-
crease) in P69 cells, a normal prostate epithelial cell line,
indicating that metformin may specifically target the
proliferation of PCa cells over normal cells [222]. Met-
formin-induced cell cycle inhibition was accompanied by
a strong decrease of the level of cyclin D1 and an in-
crease in p27 protein expression, which is typically
observed by inhibition of mTORC1 [46,96,222]. In con-
trast, AR stimulation by DHT in LNCaP cells caused
increased expression of cyclin D1, D2 and D3 and stimu-
lated cell cycle progression [96]. Metformin inhibits
mitochondrial respiratory chain complex I, which
reduces ATP production, and thereby activates LKB1
and AMPK [223]. AMPK inhibits mTORC1 by direct
phosphorylation of TSC2 and Raptor [57,60,224]
(Figure 5). It has been demonstrated that metformin in
combination with the glucose antagonist 2-deoxyglucose
induced AMPK-dependent apoptosis of PCa cells [225].
Recently, a further inhibitory mode of metformin ac-
tion on mTORC1 activity has been demonstrated, which
interferes with leucine signaling. Metformin and phen-
formin have been shown to inhibit amino acid-
dependent Rag GTPase-mediated mTORC1 activation
[226]. Metformin disturbed leucine-dependent Rag
GTPases required for translocation of inactive mTORC1
to activated Rheb enriched in lysosomal membranes,
thereby reducing mTORC1 activity [53,55,227]. Similar
to the effect of amino acid withdrawal, treatment of cells
growing in amino acid-rich media in the presence of
phenformin caused mTORC1 to leave the perinuclear
intracellular compartment and to disperse throughout
the cytoplasm without affecting amino acid steady state
levels. It is thus conceivable that the biguanide metfor-
min (C4H11N5; molar mass 129.1) functions as a com-
petitive inhibitor of leucine (C6H13NO2; molar mass
131.2) in the Rag GTPase-dependent process of
mTORC1 activation. Notably, the daily dose of metfor-
min (2 g/day) is in the range of leucine intake derived
from daily consumption of 100 g meat or cheese. Thus,
disruption of leucine-mediated mTORC1-signaling by
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tivity in PCa. Moreover, the combination of metformin
treatment of patients receiving ADT would potentiate
the treatment effect on mTORC1 signaling as ADT
reduces intracellular leucine uptake, while metformin
suppresses leucine-mediated translocation of inactive
mTORC1 to lysosomal compartments enriched in acti-
vated Rheb.
Decreased leucine uptake and attenuated mTORC1
signaling by plant-based diets
The balance of a plant-based as opposed to dairy and
animal protein-enriched diet has been appreciated as an
important factor for the prevention of PCa [228]. Evi-
dence has been provided that a diet emphasizing plant
over animal product intake has been associated with
decreased risk and less aggressive course for PCa [229].
On the other hand, the intake of dairy products and red
meat has been associated with increased risk, while the
intake of vegetables, especially cruciferous vegetables
and tomato products, was associated with a decreased
risk of PCa. [230-233]. The potential PCa-protective
effect of a plant-based diet may be explained by the re-
duction of dairy- and animal meat-derived leucine in-
take, and especially lower insulin and IGF-1 signaling of
non-dairy plant-based diets attenuating overall mTORC1
activity. Moreover, diets emphasizing plants, especially
cruciferous vegetables, not only decrease leucine-
dependent mTORC1 activation but they provide natural
plant-derived inhibitors of mTORC1.
Natural plant-derived mTORC1 inhibitors
mTORC1 activation by leucine-rich dairy consumption
may be attenuated by natural plant-derived inhibitors of
mTORC1. Increasing studies have demonstrated that
3,3´-diindolylmethane (DIM), epigallocatechin gallate
(EGCG), genistein, curcumin, resveratrol and caffeine, all
inhibit mTORC1 signaling directly or indirectly and
have been suggested to reduce the risk of PCa and other
common cancers [234-251].
Especially, the consumption of cruciferous vegetables
has been associated with a decreased risk of PCa
[244,245,250]. 3,3´-Diindolylmethane (DIM) is generated
in the acidic environment of the stomach following
dimerization of indole-3-carbinol monomers present in
cruciferous vegetables such as broccoli, brussel sprouts,
cauliflower and cabbage. DIM suppresses signaling
through Akt/mTORC1 pathways resulting in cell cycle
arrest [250]. Recent studies have shown that PDGF-D
and its cognate receptor PDGFR-β are expressed in
prostate tumor tissues, suggesting that PDGF-D might
play an important role in the development and progres-
sion of PCa. Overexpression of PDGF-D in PC-3 cells
resulted in rapid growth and enhanced cell invasion thatwas associated with activation of mTORC1 [245]. B-
DIM significantly inhibited both mTORC1 and Akt in
PC-3 PDGF-D cells associated with decreased cell prolif-
eration and less invasion [245].
Laboratory and clinical studies have demonstrated that
green tea components, specifically the green tea catechin
epigallocatechin gallate (EGCG), can induce apoptosis,
suppress progression, and inhibit invasion and metasta-
sis of PCa [251]. There is substantial animal and in vitro
evidence supporting the chemopreventive effects of
green tea polyphenols in PCa [252,253]. Tea polyphenols
have been detected in prostate tissue in humans after
green tea consumption [254]. Intriguingly, EGCG has
been proven to function as an ATP-competitive inhibitor
of both PI3K and mTORC1 catalytic units [241].
In LNCaP prostate cancer cells, the naturally occur-
ring phytopolyphenol compound resveratrol inhibited
the phosphorylation of PI3K, Akt and mTORC1 and
induced growth arrest and apoptosis through mTORC1
inhibition and activation of FoxO transcription factors
[255].
Thus, accumulating evidence from studies of plant-
derived mTORC1 inhibitors implies that a higher con-
sumption of vegetables, predominantly cruciferous
vegetables in association with green tea consumption
may antagonize increased mTORC1 signaling induced by
high consumption of dairy proteins. Diets emphasizing
vegetables and fruits and restricting dairy products, iso-
lated sugars and cereal grains (which typically have high
glycemic loads), like Paleolithic type diets, are associated
with reduced insulin and IGF-1-signaling and higher in-
take of plant-derived mTORC1 inhibitors. It is likely that
plants have evolved various natural mTORC1 inhibitors
to defend invading opportunistic organisms by attenuat-
ing their TOR-dependent growth and metabolic activity.
Dairy protein consumption during critical growth phases
of the prostate gland
At least three major mTORC1-dependent growth phases
exist in humans, which affect the growth and develop-
ment of the prostate gland as well: fetal and postnatal
growth of the prostate and sexual maturation of the
prostate during puberty. The Danish National Birth Co-
hort from 50,117 mother-infant pairs provided evidence
that increased total daily dairy protein consumption dur-
ing pregnancy increased the neonate´s size at birth and
was linearly correlated with increased birth weight [256].
Dairy protein-activated mTORC1 signaling may increase
placental growth, which augments the transfer of glucose
and amino acids to the fetus thus promoting fetal
growth [257,258]. It is conceivable that increased dairy
protein intake during pregnancy not only stimulates gen-
eral growth and size of the fetus but may also affect the
growth of the prostate during fetal development.
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event requiring precise temporal and spatial integration
of numerous hormonal and growth factor-regulated
inputs. Gosh et al. recently demonstrated that PI3K/
mTOR activity is robustly induced by androgen during
murine prostatic development and showed that PI3K/
mTOR signaling is necessary for prostatic epithelial bud
invasion of surrounding mesenchyme [259]. These data
point to an important role for PI3K/mTOR signaling in
prostatic epithelial invasion and migration and implicate
the maintenance of a fine tuned balance of PI3K-mTOR
activity as a most critical regulatory circuit for prostatic
epithelial morphogenesis [259]. It has been suggested
that some of the same signaling pathways may be
required for both prostatic morphogenesis and prostate
tumorigenesis. Organ morphogenesis is not completed
after birth and final organ maturation exceeds into the
postnatal feeding period.
It is thus of serious concern that currently available
cow´s milk-based infant formula provides excessive leu-
cine per feeding content in comparison to the physio-
logical leucine content of human breast milk [100-113].
Serum leucine, total IGF-1 as well as insulin serum con-
centrations are significantly higher in formula-fed infants
compared to breast-fed infants [113]. Median serum
concentrations of leucine at 6 months of age were lowest
in breast-fed infants (106 μmol/L) compared to infants
either fed low-protein formula (120 μmol/L) or high
protein formula (165 μmol/L) [113]. Thus, cow´s milk-
derived infant formula does not meet the physiological
lower leucine signaling axis required for adequate
mTORC1 regulation of the human newborn. These post-
natal aberrations of leucine-mediated mTORC1 signal-
ing may have an adverse effect on mTORC1-mediated
postnatal prostate morphogenesis, thereby priming
metabolic deviations that ultimately promote prostate
tumorigenesis.
Not only the perinatal growth phase but also puberty-
dependent growth and sexual maturation of the prostate
requires appropriate signaling to maintain adequate
mTORC1-activity during this sensitive period of sexual
gland differentiation. In fact, recent epidemiological evi-
dence supports the view that high intake of milk during
puberty increased the risk of advanced PCa in adult life,
thus questioning the attitude of promoting school milk
consumption during puberty and adolescence [30].
Targeted therapy for prostate cancer by inhibition of the
PI3K/Akt/mTOR pathway
Leucine stimulation alone is sufficient to stimulate
mTORC1 signal transduction [54]. Activation of mTORC1/
S6K1 signaling is widespread in a number of human can-
cers [260]. Currently, oncology pays special attention to the
prominent role of the activated PI3K/Akt/mTOR pathwayin PCa, which has led to the development of multiple new
drugs for targeted therapy of PCa [261-264]. Molecular
changes in the PI3K/Akt/mTOR signaling pathway have
been demonstrated to differentiate benign from malignant
prostatic epithelium and are associated with increasing
tumor stage, grade, and risk of recurrence [261-264]. AR
transcriptional activity as well as AR expression is regulated
by Akt [265]. In addition, androgens regulate the Akt path-
way by both genomic and non-genomic effects [265]. At
this stage, several inhibitors of the mTOR pathway are
being assessed in laboratory and clinical trials underlining
the pivotal role of aberrant mTOR signaling in PCa tumori-
genesis [263]. It has recently been demonstrated that the
ATP site mTOR inhibitor INK128 inhibited PCa progres-
sion in mice by inhibiting oncogenic mTORC1 signaling
[91].
Pharmacological mTORC1 inhibitors thus counteract
BCAA, insulin and IGF-1-induced overstimulation of
mTORC1 signaling stimulated by the consumption of
dairy protein-enriched Western diet.
Conclusion
Routine cow´s milk consumption of another species`
milk is an evolutionary novel dietary behavior that has
the potential to alter human life history parameters and
may have long-term adverse health effects [109]. Histor-
ically, the advantage of cow´s milk consumption has
been associated with reduced infant mortality, improved
fertility, increased BMI in children, earlier onset of me-
narche and increased linear growth during adolescence
[105,106,109]. However, these at first glance “beneficial”
effects may become adverse effects later in life, especially
in Western populations with a higher life expectancy.
The clinical manifestation of PCa is a disease of the
elderly. However, the initiation phase of PCa may begin
as early as fetal growth.
Our understanding of mammalian milk has changed
from a “simple food” to a species-specific endocrine sig-
naling system. Milk´s functionality depends on its stimu-
lation of the nutrient-sensitive kinase mTORC1, the
critical hub regulating cell growth, proliferation, autop-
hagy and metabolic programming. Increased cow´s milk
and dairy protein consumption during pregnancy, the
period of postnatal infant formula feeding and milk/dairy
protein consumption in childhood, adolescence as well
as adulthood may promote and maintain abnormally
high mTORC1 signaling modifying physiological signal-
ing and mRNA patterns required for adequate tissue
morphogenesis and programming resulting in long-term
adverse effects on prostate health. Dairy protein-derived
activation of mTORC1 signaling may disturb most sensi-
tive “windows” of mTORC1-dependent metabolic pro-
gramming and autophagy regulation thereby upsetting
developmental programming and regular differentiation
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thought may explain the observed cancer-protective ef-
fect of prolonged breast-feeding, which ensures the
physiological mTORC1-signaling axis provided by
human milk. Increased mTORC1-signaling due to cow´s
milk consumption during puberty may explain the asso-
ciation between frequent cow´s milk consumption dur-
ing adolescence and higher risk of aggressive PCa in
adulthood [30,266].
Sufficient evidence has accumulated to justify the re-
jection of the “high dairy calcium –low vitamin D-hy-
pothesis” of PCa [38], whereas the intrinsic signaling
capability of milk proteins along with orally bioavailable
estrogen metabolites present in milk from pregnant cows
represents a more likely explanation for the role of dairy
consumption in the development and progression of
PCa in Western countries [6,10,42]. As mTORC1-
mediated cow´s milk signaling shares the same down-
stream pathways as oncogenic mTORC1 signaling of
prostate epithelial cells with growth-promoting genetic
aberrations, increased intake of cow´s milk and dairy
proteins may exaggerate already increased mTORC1 sig-
naling of PCa cells. Thus, cow´s milk is not a simple nu-
trient but an endocrinological effector that provides a
pro-survival and anti-autophagy tissue environment pro-
moting the initiation and progression of PCa (Figure 5).
In contrast, plant-based dietary regimens are associated
with reduced intake of insulinotropic and IGF-1 elevat-
ing amino acids as well as cow´s milk-derived estrogens
and in contrast increase the uptake of potential cancer-
preventive natural mTORC1 inhibitors. Hormonal abla-
tion therapy (ADT), metformin treatment, natural
mTORC1 inhibitors and targeted therapy with synthetic
mTORC1 inhibitors just share a common mode of ac-
tion: the attenuation of increased mTORC1 activity,
which is increased by high milk and dairy protein
consumption.
In 1994, Ross and Henderson [267] have asked: “Do
diet and androgens alter prostate cancer risk via a com-
mon etiologic pathway?” Today, this question may be
well explained by androgen- and milk-mediated syner-
gisms in prostate mTORC1 signaling [97]. From an evo-
lutionary perspective it can be concluded that the
persistent “abuse” of the growth-promoting signaling
system of bovine milk by humans over their entire life
span maintains the most important hallmark of cancer
biology, i.e., sustained proliferative signaling [102]. The
magnitude of mTORC1 signaling of Western diet
appears to be much higher than that of Paleolithic diets
[133], which are less insulinotropic, provide lower gly-
cemic load and exclude the intake of cow´s milk pro-
teins [268-271]. In the 1930s leaders of pediatrics were
convinced that human breast milk is “just food” [272].
According to this simplified misconception of milk´sbiology no further efforts were undertaken to explore
milk´s growth-promoting signal transduction pathways,
allowing the widespread introduction of cow´s milk-
based infant formula feeding. Subsequent evidence has
clearly demonstrated that cow´s milk-based infant for-
mula substantially exceeds the insulin, IGF-1 and leucine
serum concentrations of formula-fed infants in compari-
son to breast-fed infants [110-113]. Daily intakes of
500 ml cow´s milk for children are still routinely recom-
mended by leading pediatricians [158]. This advice
means that one third of daily total protein intake
(recommendation 56 g) in the age-range for 14-18 year-
old boys will be administered in form of growth-promot-
ing signaling proteins and not by structural proteins like
meat or fish. Because adolescence represents a most crit-
ical mTORC1-dependent period of prostate differenti-
ation and the subsequent increased risk for PCa [30], the
medical community urgently needs to re-evaluate dietary
milk recommendations. Dietary recommendations for
children and adolescents require nutrient intakes, which
allow an adequate and undisturbed period for prostate
morphogenesis and sexual maturation of the prostate
gland. In this context, it is of serious concern, that in-
creasing numbers of adolescents and young men con-
sume 60 to 80 g of highly insulinotropic whey protein
concentrates daily to gain muscle mass [273]. Thus, fu-
ture dietary studies should clarify the impact of
increased cow´s milk protein intake upon early steps of
prostate morphogenesis and differentiation. It will be-
come important in future experimental work to define
safe upper limits for long-term milk and dairy intake for
the prevention of the most common dairy-promoted
cancer in men.Abbreviations
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